14 December 2016 - The guidance relates to the use of ticagrelor for the prevention of atherothrombotic events after myocardial infarction.

Ticagrelor, when used in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event.

Treatment should be stopped when clinically indicated or at a maximum of 3 years.

Read NICE guidance for Brilinta (ticagrelor)